Close

Oppenheimer Downgrades Corcept Therapeutics (CORT) to Perform

Go back to Oppenheimer Downgrades Corcept Therapeutics (CORT) to Perform

Corcept Therapeutics, Inc. (CORT) Tops Q3 EPS by 1c

October 31, 2012 4:51 PM EDT

Corcept Therapeutics, Inc. (NASDAQ: CORT) reported Q3 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $2.07 million.

For earnings history and earnings-related data on Corcept Therapeutics, Inc. (CORT) click here.... More